Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs) (Seva)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Center for Health Enhancement System Studies
Sponsor:
Collaborators:
Dartmouth-Hitchcock Medical Center
Information provided by (Responsible Party):
Andrew Quanbeck, Center for Health Enhancement System Studies
ClinicalTrials.gov Identifier:
NCT01963234
First received: October 9, 2013
Last updated: May 12, 2015
Last verified: May 2015

October 9, 2013
May 12, 2015
March 2014
June 2017   (final data collection date for primary outcome measure)
Implementation status [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
To measure implementation progress, we will adapt our implementation model intervention into a specific implementation plan (including timetables) for each clinic. We employ the Stages of Implementation Completion model (Chamberlain et al., 2011) to assess the degree of implementation. Each of the 8 phases of the implementation completion model is prospectively broken down into discrete tasks and events. We will assess whether each task/event was implemented and the length of time each one took to implement. Starting at the beginning of the implementation planning period (4 months before the first patient accesses Seva), the checklist will be reviewed and updated monthly by the implementation program leader, with responses verified by the clinic coach.
Same as current
Complete list of historical versions of study NCT01963234 on ClinicalTrials.gov Archive Site
  • Number of patients using system [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • Clinical adoption [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
    We will analyze computerized system log files to produce metrics about patterns of system adoption by patients and staff. We will assess the characteristics of staff members (job function, years with clinic, etc.) and patients (age, gender, race, etc.) to determine individual characteristics associated with the degree of adoption.
Same as current
Not Provided
Not Provided
 
Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)
Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)

Implementing a mobile-phone based system for drug use disorders in primary care settings.

The purpose of the research is to study the impact of a recovery support system called Seva on primary care organizations, where issues such as coordination of care, job satisfaction, and the cost of adopting and operating new technologies are critical. The study will also investigate how to best implement this kind of technology into health care delivery systems that care for people diagnosed with substance abuse.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients of federally qualified health centers with drug use disorders.

  • Substance Use Disorders
  • HIV
Not Provided
Seva
Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
Quanbeck AR, Gustafson DH, Marsch LA, McTavish F, Brown RT, Mares ML, Johnson R, Glass JE, Atwood AK, McDowell H. Integrating addiction treatment into primary care using mobile health technology: protocol for an implementation research study. Implement Sci. 2014 May 29;9:65. doi: 10.1186/1748-5908-9-65.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
June 2017
June 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patient subjects must be 1) age 18 or older 2) meet criteria for Substance Use Disorder (SUD) according to the clinic. Clinician subjects referring patients will ensure that patients: 3) have no current psychotic disorder severe enough to prevent participation, 4) have no acute medical problem requiring immediate inpatient treatment, 5) are willing to use Seva, and 6) can understand and sign a consent form in English.

Clinician subjects include MDs, behavioral health providers, nurses and management staff from the clinics' primary care and behavioral health departments. Clinician must have an interest in the research objectives.

Exclusion Criteria:

  • Failure to meet inclusion criteria above will exclude patients and clinicians from participating.
Both
18 Years and older
Yes
Contact: Fiona M McTavish, MS 608-262-7852 fiona.mctavish@chess.wisc.edu
Contact: Andrew R Quanbeck, Ph.D. 608-890-1016 andrew.quanbeck@chess.wisc.edu
United States
 
NCT01963234
R01 DA034279-01, R01DA034279-01
Yes
Andrew Quanbeck, Center for Health Enhancement System Studies
Andrew Quanbeck
  • National Institute on Drug Abuse (NIDA)
  • Dartmouth-Hitchcock Medical Center
Not Provided
Center for Health Enhancement System Studies
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP